^
Association details:
| Biomarker: | CD79B mutation |
|---|---|
| Cancer: | Diffuse Large B Cell Lymphoma |
| Drug: | Venclexta (venetoclax) (Bcl2 inhibitor) + Imbruvica (ibrutinib) (BTK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A genetic predictive model for precision treatment of diffuse large B-cell lymphoma with early progression
Published date:
08/26/2020
Excerpt:
BCL2 inhibitor venetoclax was added to enhance the effectiveness of ibrutinib and AZD 1208...CD79B-mutant Val cells and PIM1-mutant OCI-Ly8 cells were more sensitive to Ibrutinib (10 μM)- and AZD 1208 (40 μM)-induced apoptosis (p < 0.01)...Venetoclax (0.1 μM) showed the most synergistic effect on Ibrutinib (10 μM)- and AZD 1208 (40 μM)-induced apoptosis (p < 0.01).
DOI:
10.1186/s40364-020-00214-3
